Counterfeit Retatrutide Tears Oesophagus, Australia's TGA Warns

Australia’s medicines regulator has linked a counterfeit vial sold as the experimental weight-loss drug retatrutide to a torn oesophagus. Laboratory testing found the product contained no retatrutide at all, and instead carried undeclared semaglutide at roughly eight times the level detected in semaglutide products the regulator has assessed. The Therapeutic Goods Administration safety advisory, published Monday 14 September 2026, is the latest in a string of warnings the agency has issued against unapproved peptide products.

What the Testing Found

The TGA reported that a consumer who used a product sold as retatrutide experienced uncontrollable vomiting, was hospitalised, and suffered a torn oesophagus. Analysis established two separate failures: the vial contained no retatrutide, and the substance it did contain — semaglutide, the active ingredient in Ozempic and Wegovy — was present in an amount the regulator described as approximately eight times higher than the level found in semaglutide products assessed by the TGA and included in the Australian Register of Therapeutic Goods. For the assay detail and the regulator’s source links, see the September 2026 TGA laboratory result that found undeclared semaglutide and no retatrutide.

Retatrutide remains an investigational medicine. The TGA confirmed it is currently undergoing clinical trials in humans, has not been approved by the TGA or any comparable international regulator, and stated that any retatrutide product accessed outside a clinical trial setting could be counterfeit and should not be used.

Independent testing has repeatedly found that black-market vials labelled as retatrutide do not match their own labels — what that dose-accuracy testing showed.

Why a Torn Oesophagus Is the Specific Harm

A ruptured oesophagus is not a marginal adverse event. Melbourne gastroenterologist Darcy Holt told the ABC the injury is time-critical.

“Without prompt medical attention a ruptured oesophagus is almost universally fatal,” Dr Holt said. He explained the mechanism: a tear allows stomach contents to enter the part of the body housing the heart and major blood vessels, where infection and inflammation become extremely serious.

Dr Holt drew a direct line from excess drug exposure to the injury. “Many of the peptides we are talking about do have gastrointestinal effects and require titration of dose to minimise those effects,” he said. “But in overdose, the gastrointestinal effects can be severe. A high dose of the drug can cause extreme nausea and forceful vomiting leading to an oesophageal tear.”

He said he had also treated patients for liver toxicity and severe secretory diarrhoea after unapproved peptide use, and that the clinical picture had shifted sharply this year. “Over the past three to six months the use of peptides like retatrutide has gone from something that basically we would never elicit from a patient’s medication list to something that now quite frequently pops up.”

The Vial Problem: Identity, Not Just Dose

The TGA’s Chief Medical Advisor, Professor Robyn Langham, framed the risk as one of unknown contents rather than miscalculated quantities alone.

“The biggest risks with unapproved peptide products are not knowing what is in the vial, how much of, or even what substance it contains, whether its sterile or whether it contains other contaminants or toxins,” Professor Langham said. “These risks are particularly concerning for injectable products, where contaminated or non-sterile manufacturing can increase the risk of infection and harmful immune responses including anaphylaxis.”

That describes this case precisely: the harm came not from a mislabelled dose of the drug the buyer thought they were getting, but from a substituted substance at an unverified concentration. Related reporting has documented liver failure following counterfeit peptide use and earlier Australian cases that prompted batch-testing calls after liver toxicity reports.

What the Regulator Is Asking

The TGA said consumers should not use unapproved peptide products, particularly those supplied in unmarked vials, purchased online, or obtained from overseas, and that its investigations are attempting to locate the source and supply of unapproved peptides in Australia and remove them from the market.

Professor Anthony Lawler, Head of the TGA, said the case underscored the limits of consumer-side risk assessment. “Consumers must understand that the safety of these imported products is not assessed by the TGA,” he said. “They are not subject to the same controls over the quality or efficacy of the goods when compared with medicines approved for supply in Australia.”

The enforcement posture has been building. In June 2026 the TGA expanded its priority focus areas to include unapproved peptide products, reflecting what it described as a scaling up of regulatory attention — a shift covered at the time in Australia’s TGA warning as global enforcement widened.

Dr Terri-Lynne South, chair of RACGP Specific Interests Obesity, told newsGP the recurring clinical difficulty is patient-side certainty. “It shows that people don’t really know what they’re getting, and you can’t be guaranteed that you get what you think you’re getting,” she said. “Particularly in this case, the excessive dose is really worrisome from a safety point of view.”

A Second Regulator, the Same Week

Australia was not the only jurisdiction acting. Thai police and the Food and Drug Administration announced on 11 September 2026 that they had seized unregistered peptide injection products and equipment worth more than 52 million baht from a house in Nonthaburi, advertised under the name Haus of peptide for weight loss. Investigators alleged the operation dispatched about 100 boxes a day at 2,900 baht each.

Thai FDA secretary-general Supattra Boonserm urged the public to avoid unregistered injections, warning that buyers could receive counterfeit products, products without the claimed active ingredient, or substances whose contents and production standards were unknown.

The two actions are legally independent, but they share one structural feature: unapproved injectable peptide products distributed with no assurance of identity, concentration, or sterility — the same gap that left an August case unpredictable well into a hospital workup. The same gap then crossed into US security policy, when twenty state attorneys general asked the White House to treat Chinese-sourced GLP-1 as a national-security problem.

Thailand went further than seizure. Since 15 September 2026, injectable GLP-1 products sold there are prescription-only, and a buyer can check the serial number printed on a box against Thailand’s FDA pilot serialisation service — how other countries verify peptide vials sets out the rule and the check.

Frequently asked questions

Is retatrutide approved for use anywhere?

The TGA states that retatrutide is currently undergoing clinical trials in humans and has not been approved by it or any comparable international regulator. For background, see retatrutide legality and risks.

What did the counterfeit vial actually contain?

No retatrutide. Testing found undeclared semaglutide at approximately eight times the level found in semaglutide products assessed by the TGA and included in the Australian Register of Therapeutic Goods.

Did this case change Australia’s compounding rules?

No. The TGA action is a safety advisory plus ongoing enforcement, not a change to the compounding framework. The regulator added unapproved peptide products to its priority focus areas in June 2026.

What should someone do if they have used an unapproved peptide product?

The TGA advises consumers not to use these products and directs anyone who is unwell after using one to seek assessment from a licensed healthcare professional. Suspected non-compliance can be reported to the TGA. PeptidesBeat does not provide medical advice and does not recommend products or doses.

How do you tell a genuine product from a counterfeit one?

You generally cannot from the outside, which is the regulator’s core point. Documented markers include unmarked vials, overseas or social-media supply, absent registration numbers, and labels that test out of specification — how counterfeit peptide products are identified.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.